DBV Technologies (DBVT) Net Cash Flow (2020 - 2026)
DBV Technologies (DBVT) posted Net Cash Flow of -$53.1 million for Q2 2026, down 234.43% sequentially from $39.5 million in Q1 2026, and down 163.9% YoY from $83.1 million in Q2 2025.
DBV Technologies (DBVT) Net Cash Flow (2020 - 2026) Analysis & Trends
DBV Technologies has reported Net Cash Flow for 7 years, with the latest figure at -$53.1 million in Q2 2026.
- Quarterly Net Cash Flow fell 163.9% year-over-year to -$53.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.0 million (up 159.74% YoY) and the FY2025 annual result came in at $153.6 million, up 246.81% from the prior year.
- Net Cash Flow declined to -$53.1 million in Q2 2026 per DBVT's latest filing, from $39.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $184.9 million in Q2 2022 and troughed at -$53.1 million in Q2 2026.
- A 5-year average of $5.6 million and a median of -$20.4 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 1200.0% in 2023, then jumped 1242.17% in 2025.
- Over 5 years, Net Cash Flow stood at -$24.2 million in 2022, then surged by 41.9% to -$14.1 million in 2023, then advanced by 23.31% to -$10.8 million in 2024, then surged by 1242.17% to $123.2 million in 2025, then plunged by 143.11% to -$53.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$53.1 million, $39.5 million, and $123.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | -53.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.10 Mn |
| Jun 30, 2026 | -53.10 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Dec 31, 2025 | 123.17 Mn |
| Dec 31, 2025 | 123.17 Mn |
| Sep 30, 2025 | -32.54 Mn |
| Sep 30, 2025 | -32.54 Mn |
| Jun 30, 2025 | 83.10 Mn |
| Jun 30, 2025 | 83.10 Mn |
| Mar 31, 2025 | -20.10 Mn |
| Mar 31, 2025 | -20.10 Mn |
| Dec 31, 2024 | -10.78 Mn |
| Dec 31, 2024 | -10.78 Mn |
| Sep 30, 2024 | -22.56 Mn |
| Sep 30, 2024 | -22.56 Mn |
| Jun 30, 2024 | -34.42 Mn |
| Jun 30, 2024 | -34.42 Mn |
| Mar 31, 2024 | -36.89 Mn |
| Mar 31, 2024 | -36.89 Mn |